Trial Now Recruiting: A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (NCT05967689)
WHY IT MATTERS
This trial targets EGFR exon 20 insertion mutations in advanced NSCLC, a genetic subtype that historically has limited treatment options and poor response to standard EGFR inhibitors.
Researchers are testing a new drug called zipalertinib to treat advanced lung cancer in patients who have a specific genetic mutation called EGFR exon 20 insertion. This mutation makes lung cancer harder to treat with standard medications. The study is looking for 220 patients to see if zipalertinib is safe and effective for this type of cancer.
NCT ID: NCT05967689 Status: RECRUITING Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations Phase: PHASE2 Enrollment: 220 Sponsor: Taiho Oncology, Inc. Summary: The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.
YOU CAN ACT ON THIS
If you have advanced NSCLC with EGFR exon 20 insertion mutations, contact the trial sponsor (Taiho Oncology) or visit clinicaltrials.gov (NCT05967689) to check eligibility and find participating sites near you.